


Antiviral agent 35

Cat. No.:	HY-155731
CAS No.:	2760972-52-7
Molecular Formula:	C ₂₃ H ₁₈ N ₂ O ₄ S
Molecular Weight:	418.47
Target:	Influenza Virus
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antiviral agent 35 (compound 4d) is an orally active and potent influenza virus inhibitor, acting function in the early stage of virus replication. Antiviral agent 35 inhibits ROS accumulation, autophagy and apoptosis induced by influenza virus, and also inhibits inflammatory response mediated by RIG-1 pathway in mouse model with pulmonary infection. Antiviral agent 35 shows little cytotoxicity with CC ₅₀ >800 μM in MDCK cells, and anti-H1N1 (A/Weiss/43) activity with EC ₅₀ of 2.28 μM ^[1] .
IC₅₀ & Target	EC ₅₀ : 2.28 μM (H1N1 A/Weiss/43), 3.34 μM (A/Virginia/ATCC2/2009), 6.61 μM (A/California/2014) ^[1]
In Vitro	Antiviral agent 35 (compound 4d) (25 μM, 50 μM; 24-72 h) inhibits influenza virus replication in MDCK cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Antiviral agent 35 (compound 4d) (25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d; by gavage; 2-6 d) attenuates pulmonary inflammation in mice on the 2nd, 4th and 6th day after H1N1 infection ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ge Y, et al. Synthesis and pharmacodynamic evaluation of naphthalene derivatives against influenza A virus in vitro and in vivo. *Eur J Med Chem.* 2023 Nov 5;259:115660.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA